Action Allurion Technologies (ALUR)
Société cotée en bourse. Voici le cours, un aperçu de l'activité et l'essentiel à savoir sur Allurion Technologies en novembre 2026.
Allurion Technologies is a medical-device company focused on non-surgical weight-loss solutions, most notably a swallowable gastric balloon and a digital programme to support patient weight management. The company operates in the obesity-treatment segment, combining a device with remote monitoring and clinical services. For investors this is a micro-cap idea: market capitalisation is small and liquidity can be limited, which tends to increase share-price volatility and execution risk. Potential attractions include exposure to a growing global demand for less-invasive obesity therapies and the possibility of scaling via clinic partnerships, tech-enabled follow-up and new markets. Key risks include regulatory and clinical outcomes, competition from established device makers and drug therapies, uncertain revenue visibility and the potential need for additional financing. This summary provides general educational information only and is not personal advice. Values can rise and fall; investors should assess company filings, clinical data and market dynamics, and consider suitability for their own risk tolerance.
Performance de croissance sur six mois
Aperçu de la performance de l'action
Note des analystes
Analysts recommend buying Allurion's stock with a target price of $5.25, indicating strong growth potential.
Santé financière
Allurion Technologies is performing well with good revenue and cash flow, showing strong profitability.
Voyez plus d'actions en téléchargeant l'application GRATUITEMENT
Cela ne prend que 60 secondes.
Pourquoi vous voudrez suivre cette action
Market opportunity
Obesity treatment is a growing global market and less-invasive options attract interest; however, adoption can be gradual and revenue growth is not guaranteed.
Device plus software
Combining a physical device with remote monitoring and digital care can create differentiated services, though clinical outcomes and reimbursement matter for uptake.
Scale and risks
International clinic partnerships offer expansion potential, but small market cap and regulatory hurdles mean execution and financing risks are material.
Pourquoi investir avec Nemo ?
Zéro commission
Négociez actions, ETF et plus encore sans commission. Gardez une plus grande part de vos gains.
Fiable et réglementé
Membre du groupe Exinity depuis 2015, au service de plus d'un million de clients dans le monde.